Madam Speaker, pursuant to the Republican Leadership standards on member requests, I am submitting the following information regarding four (4) member requests I received as part of H.R. 2638, The Consolidated Security, Disaster…
Madam Speaker, pursuant to the Republican Leadership standards on member requests, I am submitting the following information regarding four (4) member requests I received as part of H.R. 2638, The Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009:
1. Southeast Nebraska Cancer Center Foundation/National Functional Genomics Center: $1.2 million.
Account: 30 0603002A Medical Advanced Technology.
Address of Requesting Entity: Southeast Nebraska Cancer Center Foundation, 201 South 68th Street Place, Lincoln, NE 68510-2496.
Description: $1.2 million which will be used to support current genomics-based clinical trials involving the development of molecular signatures at the National Functional Genomics Center (NFGC), concurrently supporting the development of a strong bioinformatics program. These two components are critical to the mission of the NGFC. Each requires large numbers of qualifying patients, and corresponding tissues procurement to advance translational research.
The Southeast Nebraska Cancer Center (SNCC) is comprised of a group of oncologists, health care professionals and informatics personnel who support the advancement of translational research, in conjunction with a desire to offer the best survival opportunities to patients now and in the future. As an affiliate member of the NFGC, SNCC provides clinical support for validation of ``molecular signatures'' and serves as the first clinical facility to provide patients for trials, and to establish research protocols for distance access to the NFGC.
2. Novel Coating Technologies for Military Equipment: $4.8 million.
Account: 7 0602234N Materials, Electronics, and Computer Technology.
Address of Requesting Entity: University of Nebraska-Lincoln, 301 Canfield, P.O. Box 880433, Lincoln, NE 68588-0433.
Description: $4.8 million for the University of Nebraska-Lincoln to further develop novel technologies that will enable high-performance surface coatings to be applied to airplanes, warships, tanks, and other large military equipment on site and in an open atmosphere, avoiding the current high costs in time and money of equipment disassembly and the use of vacuum chambers. Most military equipment, ranging from airplanes to warships and tanks, requires high-performance surface coatings for improved performance and reliability. Because military equipment is commonly used in harsh environments, the surface coatings quickly degrade and require periodic evaluation, repair, and often full replacement. Current coating technologies use chemical and physical vapor deposition, which requires high temperatures, the use of vacuum chambers, and disassembly of large equipment to fit in the vacuum chambers. This project will develop laser-based technologies that will deposit high performance surface coatings on site and in open atmosphere without requiring disassembly and
reassembly of the equipment. These surface coatings will have improved hardness, wear resistance, anti-corrosion, and thermal barrier properties.
3. Advanced Magnetic Nanosensors for Defense Applications: $4.8 million.
Account: 5 0602105A Materials Technology.
Address of Requesting Entity: University of Nebraska-Lincoln, 301 Canfield, P.O. Box 880433, Lincoln, NE 68588-0433.
Description: $4.8 million for the University of Nebraska-Lincoln to develop and demonstrate nanosensors with unprecedented sensitivity, reduced noise, optimal capability with electronic systems, and the capability to detect explosives, chemicals, and motion. The project addresses the Department of Defense (DoD) priority research area of nanotechnology-based warfighting with an emphasis on new devices for defense and security. These highly sensitive, miniaturized devices would be extremely useful in the creation of the distributed sensor networks that DoD sees as next generation sensor technology. Research will focus on the development of two types of sensors: magnetic tunnel junctions (MTJs) to sense extremely small magnetic fields, enabling detection of explosive devices (such as IEDs) and motion; and micro- cantilever detectors (MCDs), highly sensitive devices to detect molecules attached to magnetic nanoparticles, creating an advanced biological sensor capable of detecting a single virus or bacterium. This research will provide clear pathways for applications developers to improve signal and reduce noise, two of the critical challenges to effective nanosensors. This research will continue to build the strong infrastructure of basic trained scientists with the expertise required for Nebraska's economic development in the area of sensors and electronic devices.
4. Novel Systems for Developing Therapeutics Against Botulism: $4 million.
Account: 28 0602787A Medical Technology.
Address of Requesting Entity: University of Nebraska-Lincoln, 301 Canfield, P.O. Box 880433, Lincoln, NE 68588-0433.
Description: $4 million for the University of Nebraska-Lincoln (UNL) to develop novel processes to produce therapeutic molecules against all seven serotypes of the botulinum neurotoxin and make these processes ready for Phase I clinical studies. Botulinum neurotoxin is a biowarfare agent, a Category A CDC select agent and the most potent known toxin to humans. No FDA licensed vaccines against botulinum neurotoxin exists and there are no therapeutic molecules that can counteract its deadly effects once it enters the nerve cell. Development of such a therapeutic is the U.S. Army's highest priority for botulism research. Scientists at UNL and USAMRIID have collaborated 12 years on the first generation botulism vaccine, which has been effective against some of the original toxin, but challenges in vaccine development may render the vaccine ineffective. USAMRIID has developed and demonstrated a proof-of-concept of a new molecule that will specifically target the nerve cell. This funding will enable UNL's Biological Process Development Facility to develop novel recombinant protein expression technology to produce therapeutic molecules and make these processes ready for Phase I clinical studies. The processes also will enable the development of other therapeutics of interest to the Department of Defense.